Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Tabletop particle accelerator could transform medicine and materials science 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has approved its new therapy, Inluriyo, for the treatment of advanced or metastatic breast cancer in adult patients who have already undergone prior therapy. This milestone approval marks a significant advancement in addressing a challenging form of cancer that often resists standard treatments.
Metastatic breast cancer, also known as Stage IV breast cancer, occurs when cancer spreads beyond the breast and nearby lymph nodes to other organs such as the bones, liver, lungs, or brain. Certain breast cancers develop ESR1 mutations, which cause estrogen receptors to become overly active. While these receptors normally regulate cell growth, their mutation can accelerate cancer progression. Inluriyo directly targets these receptors by binding to and breaking them down, effectively blocking their activity to help slow disease progression.
The FDA’s decision was based on data from a late-stage clinical trial showing that patients treated with Inluriyo had a 38% lower risk of disease progression or death compared to those receiving standard therapies. On average, patients taking Inluriyo went 5.5 months without cancer worsening, versus 3.8 months with other treatments.
Inluriyo is an oral therapy recommended at a daily dose of 400 mg—taken as two 200 mg tablets on an empty stomach. The drug will be available in the U.S. within weeks at a list price of $22,500 per 28-day cycle. Eli Lilly highlighted that the medication carries an embryo-fetal toxicity warning, underscoring the risks of exposure during pregnancy.
The company is also investigating Inluriyo in combination with abemaciclib, another Lilly therapy, for advanced breast cancer, as well as in early-stage disease as adjuvant treatment.
With its approval, Inluriyo offers patients with metastatic breast cancer and ESR1 mutations a new, targeted treatment option that could improve outcomes and provide hope in one of the toughest stages of breast cancer.
